Adipose tissue macrophages secrete small extracellular vesicles that mediate rosiglitazone-induced insulin...

Area of Science:

• Metabolic disease research
• Extracellular vesicle biology
• Immunometabolism

Background:

• The global obesity epidemic exacerbates metabolic and inflammatory diseases.
• Thiazolidinediones, like rosiglitazone (Rosi), are PPARγ agonists that polarize adipose tissue macrophages (ATMs) towards an M2-like phenotype, enhancing insulin sensitization.
• ATM-derived small extracellular vesicles (ATM-sEVs) from lean mice are known to improve insulin sensitivity.

Purpose of the Study:

• To investigate the metabolic effects of ATM-sEVs derived from obese mice treated with rosiglitazone (Rosi-ATM-sEVs).
• To determine if Rosi-ATM-sEVs can ameliorate obesity-induced metabolic dysfunction.
• To identify the specific components within Rosi-ATM-sEVs responsible for their therapeutic effects.

Main Methods:

• Obese male mice were treated with rosiglitazone, and ATM-sEVs were isolated.
• The metabolic effects of Rosi-ATM-sEVs were assessed in vivo using glucose and insulin tolerance tests.
• Insulin sensitivity was evaluated in adipocytes, myotubes, and hepatocytes, with miRNA analysis performed on the sEVs.

Main Results:

• Rosiglitazone treatment improved glucose and insulin tolerance, repolarized ATMs, and increased sEV secretion.
• Administration of Rosi-ATM-sEVs rescued obesity-induced glucose intolerance and insulin resistance without causing weight gain or hemodilution.
• Rosi-ATM-sEVs directly enhanced insulin sensitivity in various cell types, with specific miRNAs, notably miR-690, identified as the key mediators.

Conclusions:

• ATM-sEVs from rosiglitazone-treated obese mice can effectively induce insulin sensitization.
• Rosi-ATM-sEVs present a promising cell-free therapeutic avenue for combating metabolic dysfunction associated with obesity.
• Targeting specific miRNAs within ATM-sEVs offers a novel strategy for developing treatments for insulin resistance.